NAV

Magaldrate

Identification

Summary

Magaldrate is an antacid used to treat various conditions in the GI tract, such as esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux.

Generic Name
Magaldrate
DrugBank Accession Number
DB08938
Background

Magaldrate is an antacid drug used for the treatment of esophagitis, duodenal and gastric ulcers, and gastroesophageal reflux. Magaldrate has been discontinued in the US market.

Type
Small Molecule
Groups
Approved, Withdrawn
Structure
Similar Structures
Weight
Average: 1115.3
Monoisotopic: 1111.7570627
Chemical Formula
Al5H33Mg10O40S2
Synonyms
  • Aluminium magnesium hydroxide sulfate hydrate
  • Aluminum magnesium hydroxide sulfate hydrate
  • Aluminum magnesium hydroxide sulphate hydrate
  • Hydrate magnesium aluminate activated sulfate
  • Magaldrate
  • Magaldrato
  • Magaldratum
  • Magnesium aluminate hydrate
  • Monalium hydrate
External IDs
  • AY 5710
  • AY-5710

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
Not Available
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Aluminium oxide: absorbed Al ions are eliminated in the urine (0.1-0.5 mg of Al in aluminium-containing antacid is absorbed from standard daily doses of antacid) while insoluble or poorly absorbed Al salts in the intestines are excreted through the feces.

Magnesium oxide: absorbed Mg ions (up to 30%) are eliminated in the urine, unabsorbed is excreted in the feces.

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Integrate drug-drug
interactions in your software
AcetaminophenMagaldrate can cause a decrease in the absorption of Acetaminophen resulting in a reduced serum concentration and potentially a decrease in efficacy.
AcetophenazineMagaldrate can cause a decrease in the absorption of Acetophenazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
Alendronic acidThe serum concentration of Alendronic acid can be decreased when it is combined with Magaldrate.
AlfacalcidolThe serum concentration of Magaldrate can be increased when it is combined with Alfacalcidol.
AlimemazineMagaldrate can cause a decrease in the absorption of Alimemazine resulting in a reduced serum concentration and potentially a decrease in efficacy.
AllopurinolThe therapeutic efficacy of Allopurinol can be decreased when used in combination with Magaldrate.
AmiodaroneThe risk or severity of hypotension can be increased when Magaldrate is combined with Amiodarone.
AmlodipineThe risk or severity of hypotension can be increased when Magaldrate is combined with Amlodipine.
AmphetamineThe serum concentration of Amphetamine can be increased when it is combined with Magaldrate.
AmprenavirMagaldrate can cause a decrease in the absorption of Amprenavir resulting in a reduced serum concentration and potentially a decrease in efficacy.
Identify potential medication risks
Easily compare up to 40 drugs with our drug interaction checker.
Get severity rating, description, and management advice.
Learn more
Food Interactions
  • Avoid alcohol.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
International/Other Brands
Almadrat T (Actavis) / Almagel T (Balkanpharma) / Antashin (Standard) / Bemolan (Nycomed) / Cremag (Zuoz) / Glysan (Riemser) / Lowsium (Rugby) / Magacid (Purzer) / Malugastrin (Polfa Lódz) / Riopan (Nycomed) / Sanaflat (Perumed)
Over the Counter Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Riopan Chewable Tablets 480mgTablet480 mgOralWyeth Ayerst Canada Inc.1994-12-312002-07-31Canada flag
Riopan Sus 480mg/5mlSuspension480 mg / 5 mLOralWhitehall Robins Inc.1993-12-312002-07-19Canada flag
Riopan Suspension 480mg/5mlSuspension480 mg / 5 mLOralWyeth Ayerst Canada Inc.1994-12-312002-07-31Canada flag
Riopan Tab 480mgTablet480 mgOralWhitehall Robins Inc.1993-12-312002-07-19Canada flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
ACITIP SUSPENSIÓNMagaldrate (8000 mg) + Simethicone (600 mg)SuspensionOralLABORATORIOS SIEGFRIED S.A.S.2018-03-26Not applicableColombia flag
ASIDOPAN PLUS 200 ML SUSPANSIYONMagaldrate (540 mg/5ml) + Simethicone (20 mg/5ml) + Sodium cation (1 mg/5ml)SuspensionOralTURGUT İLAÇLARI A.Ş.2020-08-14Not applicableTurkey flag
ASIDOPAN PLUS 30 CIGNEME TABLETMagaldrate (480 mg) + Simethicone (20 mg)Tablet, chewableOralTURGUT İLAÇLARI A.Ş.2020-08-14Not applicableTurkey flag
ASIDOPAN PLUS 60 CIGNEME TABLETMagaldrate (480 mg) + Simethicone (20 mg) + Sodium cation (1 mg)Tablet, chewableOralTURGUT İLAÇLARI A.Ş.2020-08-14Not applicableTurkey flag
ASIPODAN PLUS FORTE ÇIĞNEME TABLETI, 20 ADETMagaldrate (1080 mg) + Simethicone (20 mg)Tablet, chewableOralTURGUT İLAÇLARI A.Ş.2020-08-14Not applicableTurkey flag
ASIPODAN PLUS FORTE ÇIĞNEME TABLETI, 30 ADETMagaldrate (1080 mg) + Simethicone (20 mg)Tablet, chewableOralTURGUT İLAÇLARI A.Ş.2020-08-14Not applicableTurkey flag
ASIPODAN PLUS FORTE ÇIĞNEME TABLETI, 60 ADETMagaldrate (1080 mg) + Simethicone (20 mg)Tablet, chewableOralTURGUT İLAÇLARI A.Ş.2020-08-14Not applicableTurkey flag
GASTROFAST ADVANCEMagaldrate (8 g) + Sodium alginate (5 g) + Simethicone (1.2 g) + Sodium bicarbonate (2.67 g)SuspensionOralTECNOFAR TQ S.A.S2019-11-13Not applicableColombia flag
Riopan Plus SusMagaldrate (480 mg / 5 mL) + Dimethicone (20 mg / 5 mL)SuspensionOralWyeth Ayerst Canada Inc.1994-12-312002-07-31Canada flag
Riopan Plus SuspensionMagaldrate (96 mg / mL) + Dimethicone (4 mg / mL)SuspensionOralWhitehall Robins Inc.1993-12-312001-07-26Canada flag

Categories

ATC Codes
A02AD02 — MagaldrateA02AF01 — Magaldrate and antiflatulents
Drug Categories
Classification
Not classified
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
6V88E24N5T
CAS number
74978-16-8
InChI Key
SPPNVMTVMQOKSC-UHFFFAOYSA-A
InChI
InChI=1S/5Al.10Mg.2H2O4S.32H2O/c;;;;;;;;;;;;;;;2*1-5(2,3)4;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/h;;;;;;;;;;;;;;;2*(H2,1,2,3,4);32*1H2/q5*+3;10*+2;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;;/p-35
IUPAC Name
pentaaluminium(3+) decamagnesium(2+) hydrate hentriacontahydroxide disulfate
SMILES
O.[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Mg++].[Al+3].[Al+3].[Al+3].[Al+3].[Al+3].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O

References

Synthesis Reference

U.S. Patent 2,923,660.

General References
  1. Kurtz W: [A layered lattice antacid with long-term effectiveness. Profile of action and safety exemplified by magaldrate]. Fortschr Med. 1993 Feb 28;111(6):93-6. [Article]
  2. Varas Lorenzo MJ, Lopez Martinez A, Gordillo Bernal J, Mundet Surroca J: [Comparative study of 3 drugs (aceglutamide aluminum, zinc acexamate, and magaldrate) in the long-term maintenance treatment (1 year) of peptic ulcer]. Rev Esp Enferm Dig. 1991 Aug;80(2):91-4. [Article]
KEGG Drug
D04832
PubChem Compound
3086011
PubChem Substance
310264905
RxNav
29151
ChEMBL
CHEMBL3833350
Drugs.com
Drugs.com Drug Page
Wikipedia
Magaldrate
MSDS
Download (94.8 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SuspensionOral
Tablet, chewableOral
SuspensionOral800 MG/10ML
TabletOral800.00 mg
TabletOral800 MG
SuspensionOral
Tablet, chewableOral
GelOral80 MG/ML
TabletOral400 MG
GelOral1600 mg/10ml
SuspensionOral800 mg
Tablet, chewableOral800 mg
GelOral
GelOral1600 mg
SuspensionOral480 mg / 5 mL
TabletOral480 mg
TabletOral
Tablet
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-0.84Chemaxon
pKa (Strongest Acidic)-3Chemaxon
Physiological Charge-2Chemaxon
Hydrogen Acceptor Count4Chemaxon
Hydrogen Donor Count0Chemaxon
Polar Surface Area80.26 Å2Chemaxon
Rotatable Bond Count0Chemaxon
Refractivity11.53 m3·mol-1Chemaxon
Polarizability5.81 Å3Chemaxon
Number of Rings0Chemaxon
Bioavailability1Chemaxon
Rule of FiveNoChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
Not Available

Drug created at May 22, 2014 19:08 / Updated at February 21, 2021 18:52